CSF2 and rheumatoid arthritis: Clinical proof of concept for GM-CSF–targeted therapy has been demonstrated in patients with RA for antibodies targeting the GM-CSF receptor (mavrilimumab) [23–26] and targeting soluble GM-CSF (MOR103) [27].